Genascence to Present Full Data from Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, at European Society of Gene & Cell Therapy 30th Annual Congress
Genascence Corporation, a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy using technology discovered at the University of Florida, announced that data from the Phase 1 clinical trial of GNSC-001 for the treatment of osteoarthritis (OA) demonstrated that it was safe and well tolerated.
“The Horse’s Mouth” with Enrico Levi of Inzecto
The Horse’s Mouth is a talk show where Tom McManus’s guests sidle up to his bar to discuss the intersection of sports, business, and life. Today, Tom sits with Enrico Levi of Inzecto, a UF startup licensing mosquito control technology created by Levi, Roberto Pereira, and principal investigator Philip Koehler at the UF College of Agriculture and Food Sciences.
BioMérieux Receives CE Mark for Biomarker Assay for Mild TBI
BioMérieux, which signed an agreement in 2017 with Banyan Biomarkers to commercialize its TBI assay, has obtained the CE Mark for its assay to detect two biomarkers associated with mild traumatic brain injury (mTBI).
Cannabix’s MSBS Marijuana Breathalyzer Technology Advances Quantification of THC in Breath
UF startup Cannabix Technologies Inc., developer of marijuana and alcohol breath testing devices, reported its Mass Spectrometer Breath Sampler technology along with the Breath Collection Unit have been used to quantify delta-9 THC levels from smoking and edibles in humans.
Capsida Biotherapeutics Enters Strategic Collaboration With Kate Therapeutics to Manufacture KateTx’s Next-Generation Gene Therapies
Capsida Biotherapeutics Inc. and UF startup Kate Therapeutics announced a strategic partnership to leverage Capsida's expertise and adeno-associated virus (AAV) manufacturing capabilities to enable KateTx's initial internal portfolio of muscle and heart disease programs.
NovaBone’s New Bioactive Glass Syringe for Foot & Ankle
UF startup NovaBone Products, leader in synthetic biologics, announced the Alachua, Florida, company has made commercially available a new syringe for targeted delivery of its 45S5 bioactive glass putty device for the foot and ankle market. The newly launched syringe comes in both a 2.5cc and a 5cc formulation.
Atsena Therapeutics Doses First Patient in Phase I/II Clinical Trial of ATSN-201 for Treatment of X-Linked Retinoschisis
Atsena Therapeutics announced the first patient has been dosed in its Phase I/II clinical trial, the LIGHTHOUSE study, evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
Tech Tuesday: Sinmat
From smartphones to medical equipment, microchips improve technologies and transform – even save – our lives. The technology -- and the company, Sinmat -- featured in today’s Tech Tuesday makes advanced microchips possible.
National Cade Prize for Innovation Names 21 Finalists
Judges for 2023’s National Cade Prize for Innovation named this year’s 21 Fibonacci Finalists. Finalists will compete to win $10,000 in their respective category group—Agriculture and Environmental, Healthcare/Biomedical, IT/Tech, Energy, and Wildcard. One of the five category winners will be selected as the Inventivity™ Grand Prize winner and take home an additional $50,000 prize. Two UF startups -- Lactovid and Analyz -- are listed among the Fibonacci Finalists.
Atsena Therapeutics Receives FDA Clearance of an Investigational Gene Therapy for X-Linked Retinoschisis
The U.S. Food and Drug Administration (FDA) has cleared Atsena Therapeutics' Investigational New Drug (IND) application for a Phase I/II clinical trial of ATSN-201 in patients with X-linked retinoschisis (XLRS). Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness.
